Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
2(67%)

Phase Distribution

Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

completed133%
terminated267%

Recent Activity

0 active trials
Showing 3 of 3
terminatednot_applicable

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

NCT02134717
terminatednot_applicable

A Study Comparing the Influence of a Mindfulness-based Stress Reduction Program vs. Routine Management on Psychological Variables and Biological Markers Related to Immuno-inflammation Associated With Psychological Stress in Caregivers of Patients With Severe Psychiatric Disorders

NCT03745235
completed

Tacrolimus in CD3+ T Lymphocytes

NCT06342505

Clinical Trials (3)

Showing 3 of 3 trials
NCT02134717Not Applicable

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

Terminated
NCT03745235Not Applicable

A Study Comparing the Influence of a Mindfulness-based Stress Reduction Program vs. Routine Management on Psychological Variables and Biological Markers Related to Immuno-inflammation Associated With Psychological Stress in Caregivers of Patients With Severe Psychiatric Disorders

Terminated
NCT06342505

Tacrolimus in CD3+ T Lymphocytes

Completed

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3